Publication:
Molecular stratification of arrhythmogenic mechanisms in the Andersen Tawil Syndrome.

dc.contributor.authorManuel, Ana Isabel Moreno
dc.contributor.authorGutiérrez, Lilian K
dc.contributor.authorPedrosa, María Linarejos Vera
dc.contributor.authorUréndez, Francisco Miguel Cruz
dc.contributor.authorJiménez, Francisco José Bermúdez
dc.contributor.authorCarrascoso, Isabel Martínez
dc.contributor.authorPérez, Patricia Sánchez
dc.contributor.authorMacías, Álvaro
dc.contributor.authorJalife, José
dc.date.accessioned2023-05-03T13:27:23Z
dc.date.available2023-05-03T13:27:23Z
dc.date.issued2022-07-27
dc.description.abstractAndersen Tawil Syndrome (ATS) is a rare inheritable disease associated with loss-of-function mutations in KCNJ2, the gene coding the strong inward rectifier potassium channel Kir2.1, which forms an essential membrane protein controlling cardiac excitability. ATS is usually marked by a triad of periodic paralysis, life-threatening cardiac arrhythmias and dysmorphic features, but its expression is variable and not all patients with a phenotype linked to ATS have a known genetic alteration. The mechanisms underlying this arrhythmogenic syndrome are poorly understood. Knowing such mechanisms would be essential to distinguish ATS from other channelopathies with overlapping phenotypes and to develop individualized therapies. For example, the recently suggested role of Kir2.1 as a countercurrent to sarcoplasmic calcium reuptake might explain the arrhythmogenic mechanisms of ATS and its overlap with catecholaminergic polymorphic ventricular tachycardia (CPVT). Here we summarize current knowledge on the mechanisms of arrhythmias leading to sudden cardiac death in ATS. We first provide an overview of the syndrome and its pathophysiology, from the patient´s bedside to the protein, and discuss the role of essential regulators and interactors that could play a role in cases of ATS. The review highlights novel ideas related to some post-translational channel interactions with partner proteins that might help define the molecular bases of the arrhythmia phenotype. We then propose a new all-embracing classification of the currently known ATS loss-of-function mutations according to their position in the Kir2.1 channel structure and their functional implications. We also discuss specific ATS pathogenic variants, their clinical manifestations and treatment stratification. The goal is to provide a deeper mechanistic understanding of the syndrome toward the development of novel targets and personalized treatment strategies.
dc.identifier.doi10.1093/cvr/cvac118
dc.identifier.essn1755-3245
dc.identifier.pmid35892314
dc.identifier.unpaywallURLhttps://academic.oup.com/cardiovascres/advance-article-pdf/doi/10.1093/cvr/cvac118/45212643/cvac118.pdf
dc.identifier.urihttp://hdl.handle.net/10668/19756
dc.journal.titleCardiovascular research
dc.journal.titleabbreviationCardiovasc Res
dc.language.isoen
dc.organizationHospital Universitario Virgen de las Nieves
dc.pubmedtypeJournal Article
dc.rightsAttribution-NonCommercial 4.0 International
dc.rights.accessRightsopen access
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/
dc.subjectKCNJ2 mutations
dc.subjectKir2.1 mutations classification
dc.subjectKir2.1-NaV1.5 channelosome
dc.subjectchannelopathies
dc.subjectsarcoplasmic reticulum Kir2.1 channels
dc.subjectsudden cardiac death
dc.titleMolecular stratification of arrhythmogenic mechanisms in the Andersen Tawil Syndrome.
dc.typeresearch article
dc.type.hasVersionVoR
dspace.entity.typePublication

Files